ArticleInternational journal of clinical pharmacy2024

Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China.

Jingxuan Wei et al.PubMed ↗Publisher ↗

No numbers read from the abstract.